<DOC>
	<DOCNO>NCT01129063</DOCNO>
	<brief_summary>The objective study : - Assess within-subject variability pharmacokinetic profile clopidogrel active metabolite replicate single administration 75 mg clopidogrel healthy male female subject - Assess pharmacokinetic profile clopidogrel active metabolite single administration 75 300 mg clopidogrel</brief_summary>
	<brief_title>Pharmacokinetic Study Single Doses Clopidogrel , 75 mg 300 mg , Healthy Subjects</brief_title>
	<detailed_description>The total study duration per subject 4 - 6 week broken follow : - Screening : 2 21 day first dose - Period 1 , 2 3 : 4 day include 1 treatment day - Washout period : least 7 day 2 administration - End study : 7 10 day last dosing</detailed_description>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Healthy subject : determine medical history complete physical examination include vital sign clinical laboratory test body weight 50kg 95 kg male , 40.0 kg 85.0 kg female Body Mass Index ( BMI ) 18 28 kg/m2 Evidence inherit disorder coagulation/hemostasis function Smoking 5 cigarette equivalent per day Abnormal hemostasis screen Any contraindication clopidogrel Unability abstain intake drug affect haemostasis throughout whole study duration . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>